Accutane (Isotretinoin) for Adults 65+: School, Work, and Activity Considerations

At a glance

• FDA age range / 12 and older [1]
• Approved use / severe recalcitrant nodular acne unresponsive to conventional therapy [1]
• Dosing / 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks [1]
• iPLEDGE / every patient enrolled; 30-day supply, no refills [1]
• Eye effects / dry eyes, reduced visual acuity, blurred vision, decreased night vision [1]
• Avoid / vitamin A supplements and tetracyclines [1]

Is isotretinoin approved at 65 and older?

The Absorica and Absorica LD label approves oral isotretinoin for severe recalcitrant nodular acne in non-pregnant patients 12 years and older who have not responded to conventional therapy including systemic antibiotics [1]. The contraindications are pregnancy and hypersensitivity to isotretinoin, vitamin A or product components; age is not listed [1]. Absorica dosing is 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks, up to 2 mg/kg/day in very severe disease, and once-daily dosing is not recommended [1].

What iPLEDGE changes about appointments and prescriptions

Every patient is enrolled in iPLEDGE, not only patients who can get pregnant [1]. Pharmacies dispense a maximum 30-day supply with a Medication Guide and no refills, so a new prescription is needed each month [1]. Patients who can get pregnant must obtain it within 7 days of the pregnancy test collection; patients who cannot get pregnant still must not share the drug or donate blood [1].

FDA approved iPLEDGE modifications on 2026-02-09. FDA lists November 15, 2026 as the planned implementation date and says it is continuing to exercise enforcement discretion regarding pregnancy-testing requirements in the meantime [3]. The approved changes include dropping monthly counseling documentation and the 30-day prescription window for patients who cannot get pregnant [3][4].

Before treatment the label calls for a fasting lipid profile and liver function tests in all patients, with lipids monitored at regular intervals [1]. The Accutane label reports marked triglyceride elevations in approximately 25% of patients in clinical trials, an HDL decrease in about 15% and a cholesterol increase in about 7% [2]. The Accutane label says it must be taken with food because fasting significantly decreases absorption, while Absorica may be taken without regard to meals [1][2].

Eyes and vision

The label lists dry eyes, reduced visual acuity, blurred vision, asthenopia, decreased night vision which may persist and photophobia [1]. Under ocular abnormalities it says that if visual symptoms occur, treatment should be discontinued and the patient referred for an ophthalmological exam [1]. Dry eye and reduced visual acuity are common reactions at 5% or more [1].

Joints, physical work and exercise

The label lists musculoskeletal abnormalities including arthralgias, back pain and decreases in bone mineral density, and arthralgia, back pain and musculoskeletal discomfort are common at 5% or more [1]. The older Accutane label says about 16% of patients in a clinical trial developed musculoskeletal symptoms including arthralgia [2]. A cross-sectional study of 24 people on long-term retinoids found bone density below matched controls in the etretinate group but not in the nine taking isotretinoin [5].

Sun, skin and mood

The label's counseling section says to avoid prolonged exposure to UV rays or sunlight, and the Medication Guide says the drug may make skin more sensitive to light [1]. The label also says to avoid wax epilation and skin resurfacing such as dermabrasion or laser during treatment and for at least 6 months afterward because of scarring [1][2]. The label warns that isotretinoin may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide and aggressive or violent behavior [1]. A retrospective Swedish cohort of 5,756 patients aged 15 to 49, treated in the 1980s, found a raised standardized incidence ratio for suicide attempts during and up to six months after treatment, 1.78 (95% CI 1.04 to 2.85) [6].

What is not known

We found no study measuring work, school or activity outcomes specifically in adults 65 and older taking isotretinoin.

Frequently asked questions

›Can adults over 65 take isotretinoin?

The label approves oral isotretinoin for non-pregnant patients 12 and older with severe recalcitrant nodular acne unresponsive to conventional therapy, and it states no upper age limit [1]. Pregnancy and hypersensitivity are the listed contraindications [1].

›Does isotretinoin affect night vision?

The label lists decreased night vision, which may persist, along with dry eyes, blurred vision and reduced visual acuity [1]. It says that if visual symptoms occur, treatment should be discontinued and the patient referred for an ophthalmological exam [1].

›Does isotretinoin affect mood?

The label warns about depression, psychosis and rarely suicidal ideation, suicide attempts and aggressive or violent behavior [1]. A retrospective Swedish cohort of 5,756 patients aged 15 to 49 found a raised rate of suicide attempts during and up to six months after treatment [6].

›Does iPLEDGE apply to men and postmenopausal women?

Yes. All patients must be enrolled in iPLEDGE; patients who cannot get pregnant still must not share the drug or donate blood [1]. FDA approved changes in February 2026 and lists November 15, 2026 as the planned implementation date, with enforcement discretion on pregnancy testing in the meantime [3][4].

References

1. U.S. National Library of Medicine, DailyMed. Absorica and Absorica LD isotretinoin capsules (Sun Pharma) prescribing information. Absorica and Absorica LD isotretinoin capsules (Sun Pharma) label
2. U.S. National Library of Medicine, DailyMed. Accutane-format isotretinoin label (older non-PLR format) prescribing information. Accutane-format isotretinoin label (older non-PLR format) label
3. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) | FDA. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) | FDA
4. Questions and Answers on the iPLEDGE REMS | FDA. Questions and Answers on the iPLEDGE REMS | FDA
5. DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol. 1995;131(11):1263-7. Osteoporosis is a toxic effect of long-term etretinate therapy
6. Sundström A, Alfredsson L, Sjölin-Forsberg G, Gerdén B, Bergman U, Jokinen J. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ. 2010;341:c5812. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study